Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:O76050 (neu)
 3,969 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Endometriosis is a disease of unknown ethology; there are several theories that are unproven. It is known that women with such disease present with infertility, and that recurrence is very high, and apparently not depending of estrogenic stimulus. This phenomenon has been contributed to other growth factors and some oncogens. There are few studies about oncogens or other hormonal receptors; so, this study tries to evaluate them in eutopic tissue and in ectopic one of women with previous diagnosis of endometriosis. Our results show that myc as PRLr are expressed differently in the different tissues; and neu is expressed in the same way in both tissues. So, it was concluded that the cells of the endometriosis focus, have a differential status relating to expression of some of their genes, which target on their development and maintenance in a hormonal environment which differs from the uterine cavity.
 ...
PMID:[Expression of oncogenes (c-myc-neu) and prolactin receptor (PRLr) in tissues of women with endometriosis]. 1080 13

Ovarian cancer is the leading cause of death among all gynecological cancers. Some women choose bilateral oophorectomy as means of cancer prevention. In most patients, by the time this cancer is diagnosed, it has already metastasized. Treatment involves oophorectomy followed by radiation, chemo-, and immuno-therapies. However, oopherectomy results in infertility and fails to eliminate all cancer cells. Radiation and chemotherapy cause severe side effects and may lead to genetic mutations in DNA of the ova.The ultimate goal of this project is development of a therapy which would target a therapeutic gene specific to ovarian cancer cells causing their apoptosis, but which would leave ova and other cells unharmed.Herein, we report the proof of concept for such a therapy, in which genetically engineered single chain variable fragment (scFv) antibodies against HER2/ neu, RON, and NK1R, guide the delivery of the therapeutic transgenes into the cancer cells of the ovaries. Under ovary specific promoters (OSP), the transgene expression generates the intracellular scFv antibodies, which quench cell antioxidative enzymes, thus raising levels of reactive oxygen species (ROS), inflicting oxidative stress, activating apoptotic signaling pathways, and causing cancer cell deaths.
 ...
PMID:OVARIAN CANCER SUICIDE GENE THERAPY WITH GENETICALLY ENGINEERED, TRANSGENICALLY EXPRESSED, INTRACELLULAR scFv ANTIBODIES AGAINST ANTI-OXIDATIVE ENZYMES. 2324 27